Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The serum levels of activin A and bone morphogenetic protein-4 and -6 in patients with fibrodysplasia ossificans progressiva.

Orphanet journal of rare diseases - 10 May 2023

Ye Zhengqin, Wang Siyi, Shan Chang, Zhu Qi, Xue Ying, Zhang Keqin

Abstract excerpt

BACKGROUND: Fibrodysplasia ossificans progressiva (FOP) is an ultrarare and disabling genetic disorder of connective tissue characterized by congenital malformation of the great toes, and progressive heterotopic ossification (HO) in soft connective tissues. A gain-of-function mutation of activin A receptor type I (ACVR1) enables ACVR1 to recognize activin A as an agonist with bone morphogenetic protein (BMP)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Activin Receptors, Type I
Share to Bone Morphogenetic Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Myositis Ossificans

Share to Ossification, Heterotopic

Source

Open in PubMed Open full text

Identifiers

PMID: 37165433
DOI: 10.1186/s13023-023-02708-3
PMCID: PMC10170814

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The serum levels of activin A and bone morphogenetic protein-4 and -6 in patients with fibrodysplasia ossificans progressiva.PMID 37165433Read ↗

How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans ProgressivaSemantic proximity Read ↗

Fibrodysplasia ossificans progressiva: lessons learned from a rare disease.Semantic proximity Read ↗

The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva.Semantic proximity Read ↗

Twists in the fibrodysplasia ossificans progressiva story challenge and expand our understanding of BMP biology.Semantic proximity Read ↗

Fibrodysplasia ossificans progressiva.Semantic proximity Read ↗

Clinical Aspects and Current Therapeutic Approaches for FOPSemantic proximity Read ↗

Fibrodysplasia ossificans progressiva: current concepts from bench to bedside.Semantic proximity Read ↗

Fibrodysplasia ossificans progressiva emerges from obscurity.Semantic proximity Read ↗

BMP signaling and skeletal development in fibrodysplasia ossificans progressiva (FOP).Semantic proximity Read ↗

Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1.Semantic proximity Read ↗

Activin A amplifies dysregulated BMP signaling and induces chondro-osseous differentiation of primary connective tissue progenitor cells in patients with fibrodysplasia ossificans progressiva (FOP)Semantic proximity Read ↗

From mysteries to medicines: drug development for fibrodysplasia ossificans progressivaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.